<p>This study assesses glioma patient blood methylation longitudinally beginning pre-surgery through other clinically important timepoints.  Progression and survival are studied in relation to methylation derived immunologic profiles and other characteristics. For this study, patients scheduled for surgery at <a href="https://www.ucsf.edu/">University of California San Francisco</a> (UCSF) for a possible newly diagnosed glioma (grades 2-4) or recurrent grade 2/3 glioma were consented and enrolled. Patients had blood collected pre-surgery and, if the pathology results confirm a glioma, every few weeks or months during their treatment (up to 30 total timepoints). Blood immunomethylomic profiles were measured at these timepoints to assess associations with glioma patient outcomes, clinical measures, other known prognostic markers, and imaging characteristics.</p>

Immune Profiles Study

Glioma study with Methylation (CpG) data on dbGaP (135 participants)

Immune Profiles Study

Description

Applying For Access

Summary